Businesswire·2025-11-18 18:04Core Viewpoint - Rosen Law Firm has initiated a class action lawsuit against Skye Bioscience, Inc. (NASDAQ: SKYE) on behalf of investors who suffered significant losses during the specified Class Period from November 4, 2024, to October 3, 2025, due to alleged misleading statements regarding the company's business operations [1][3]. Allegations - The lawsuit claims that Skye Bioscience made materially false and misleading statements about its business, specifically regarding the effectiveness of its drug nimacimab, which was overstated, leading to inflated clinical, regulatory, and commercial prospects [3]. Class Action Participation - Shareholders interested in participating as lead plaintiffs must file motions by January 16, 2026, and can choose to remain absent class members without participating in the case [4]. Rosen Law Firm Background - Rosen Law Firm is recognized for its commitment to shareholder rights litigation, having recovered over $1 billion for shareholders since its inception, and operates on a contingency fee basis, meaning shareholders incur no fees or expenses [6].